Plasma Sphingolipids as Potential Indicators of Hepatic Necroinflammation in Patients with Chronic Hepatitis C and Normal Alanine Aminotransferase Level

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Li, Jun Feng ^a,b   Qu, Feng ^c   Zheng, Su Jun ^b   Ren, Jin Yu ^d   Wu, Hui Li ^b   Liu, Mei ^b   Liu, Hui ^b   Ren, Feng ^b   Chen, Yu ^b   Zhang, Jin Lan ^c   Duan, Zhong Ping ^b  

^a LANZHOU UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF MATERIA MEDICA   (China)

^d Evergreen Wellness Center Kansas College of Chinese Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CERAMIDE HEXOSIDE; SPHINGOLIPID; UNCLASSIFIED DRUG; BILIRUBIN; CERAMIDE; CERAMIDE TRIHEXOSIDE; GAMMA GLUTAMYLTRANSFERASE; BIOLOGICAL MARKER;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; FEMALE; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIPID BLOOD LEVEL; LIVER BIOPSY; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; NORMAL VALUE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHRONIC HEPATITIS C; CLINICAL INDICATOR; COHORT ANALYSIS; CORRELATION COEFFICIENT; DIAGNOSTIC VALUE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATIC NECROINFLAMMATION; INFLAMMATION; NECROSIS; PROTHROMBIN TIME; SCHEUER SCORING SYSTEM; SCORING SYSTEM; AGED; BIOPSY; BLOOD; ENZYMOLOGY; HEPACIVIRUS; LIVER; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; BIOPSY; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED; ROC CURVE; SPHINGOLIPIDS;

EID: 84899671398     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095095.t001     Document Type: Article

References (28)

1. Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558-567. (Pubitemid 41196755)
2. Lavanchy D (2009) The global burden of hepatitis C. Liver Int 29 Suppl 1: 74-81.
3. Ascione A, Tartaglione T, Di Costanzo GG (2007) Natural history of chronic hepatitis C virus infection. Dig Liver Dis 39 Suppl 1: S4-7. (Pubitemid 47532945)
4. Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, et al. (2003) Progression of fibrosis in chronic hepatitis C. Gastroenterology 124: 97-104. (Pubitemid 36055343)
5. Fontaine H, Nalpas B, Poulet B, Carnot F, Zylberberg H, et al. (2001) Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol 32: 904-909. (Pubitemid 32911311)
6. Bravo AA, Sheth SG, Chopra S (2001) Liver biopsy. N Engl J Med 344: 495-500. (Pubitemid 32164902)
7. Marcellin P, Levy S, Erlinger S (1997) Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 26: 133S-136S. (Pubitemid 27388086)
8. Tassopoulos NC (1999) Treatment of patients with chronic hepatitis C and normal ALT levels. J Hepatol 31 Suppl 1: 193-196. (Pubitemid 30002717)
9. Okanoue T, Makiyama A, Nakayama M, Sumida Y, Mitsuyoshi H, et al. (2005) A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol 43: 599-605. (Pubitemid 41253226)
10. Bartke N, Hannun YA (2009) Bioactive sphingolipids: metabolism and function. J Lipid Res 50 Suppl: S91-96.
11. Lingwood D, Simons K (2010) Lipid rafts as a membrane-organizing principle. Science 327: 46-50.
12. Hawkes DJ, Mak J (2006) Lipid membrane; a novel target for viral and bacterial pathogens. Curr Drug Targets 7: 1615-1621. (Pubitemid 44873723)
13. Umehara T, Sudoh M, Yasui F, Matsuda C, Hayashi Y, et al. (2006) Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model. Biochem Biophys Res Commun 346: 67-73. (Pubitemid 43884734)
14. Sakamoto H, Okamoto K, Aoki M, Kato H, Katsume A, et al. (2005) Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat Chem Biol 1: 333-337.
15. Ikeda H, Ohkawa R, Watanabe N, Nakamura K, Kume Y, et al. (2010) Plasma concentration of bioactive lipid mediator sphingosine 1-phosphate is reduced in patients with chronic hepatitis C. Clin Chim Acta 411: 765-770.
16. Jones BE, Lo CR, Srinivasan A, Valentino KL, Czaja MJ (1999) Ceramide induces caspase-independent apoptosis in rat hepatocytes sensitized by inhibition of RNA synthesis. Hepatology 30: 215-222. (Pubitemid 29300589)
17. Arora AS, Jones BJ, Patel TC, Bronk SF, Gores GJ (1997) Ceramide induces hepatocyte cell death through disruption of mitochondrial function in the rat. Hepatology 25: 958-963. (Pubitemid 27157141)
18. Mari M, Fernandez-Checa JC (2007) Sphingolipid signalling and liver diseases. Liver Int 27: 440-450. (Pubitemid 46534565)
19. Qu F, Wu CS, Hou JF, Jin Y, Zhang JL (2012) Sphingolipids as new biomarkers for assessment of delayed-type hypersensitivity and response to triptolide. PLoS One 7: e52454.
20. Qu F, Zheng SJ, Wu CS, Jia ZX, Zhang JL, et al. (2014) Lipidomic profiling of plasma in patients with chronic hepatitis C infection. Anal Bioanal Chem 406: 555-564.
21. Ghany MG, Strader DB, Thomas DL, Seeff LB (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335-1374.
22. Hepatotogy Branch, Infectious and Parasitology branch, Chinese Medical Association(2004) Guideline of prevention and treatment of hepatitis C. Zhonghua Yu Fang Yi Xue Za Zhi 38: 210-215.
23. Scheuer PJ (1991) Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 13: 372-374.
24. Lagging LM, Westin J, Svensson E, Aires N, Dhillon AP, et al. (2002) Progression of fibrosis in untreated patients with hepatitis C virus infection. Liver 22: 136-144. (Pubitemid 34591255)
25. Pagadala M, Kasumov T, McCullough AJ, Zein NN, Kirwan JP (2012) Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab 23: 365-371.
26. Biburger M, Tiegs G (2005) Alpha-galactosylceramide-induced liver injury in mice is mediated by TNF-alpha but independent of Kupffer cells. J Immunol 175: 1540-1550. (Pubitemid 41023055)
27. Inui T, Nakashima H, Habu Y, Nakagawa R, Fukasawa M, et al. (2005) Neutralization of tumor necrosis factor abrogates hepatic failure induced by alpha-galactosylceramide without attenuating its antitumor effect in aged mice. J Hepatol 43: 670-678. (Pubitemid 41253235)
28. Sanai FM, Benmousa A, Al-Hussaini H, Ashraf S, Alhafi O, et al.(2008) Is serum alanine transaminase level a reliable marker of histological disease in chronic hepatitis C infection? Liver Int 28: 1011-1018.